← Back to Search

Nerve Guide Matrix

NeuraGen 3D for Digital Nerve Injury

N/A
Waitlist Available
Research Sponsored by Integra LifeSciences Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Subject has one, single level, digital nerve injury that involves complete traumatic nerve section of the common or proper nerve of the palmar aspect of hand
Subject has adequate vascular perfusion of the target hand as assessed by the investigator
Must not have
Disorder known to affect the peripheral nervous system (PNS)
Gross contamination of the wound in which the nerve to be studied resides
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a device called NeuraGen 3D Nerve Guide Matrix, which helps repair damaged nerves. It is aimed at patients with peripheral nerve injuries and works by providing a supportive structure for nerve cells to grow back together.

Who is the study for?
This trial is for individuals who have recently (within 21 days) suffered a complete traumatic cut of specific nerves in the palm. They must be able to close the nerve gap without too much tension using the device, have good blood flow in their hand, and can keep their injured hand still after surgery. The other hand should be fully functional.
What is being tested?
The study is testing NeuraGen 3D Nerve Guide Matrix on people with digital nerve injuries. It's an initial look at how well it works and its safety over a year with ten participants across multiple centers, without comparing it to another treatment.
What are the potential side effects?
Since this summary doesn't provide specific side effects of NeuraGen 3D Nerve Guide Matrix, we can assume general risks may include infection, pain at the injury site, inflammation or allergic reactions related to implant materials.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have a single, completely cut nerve injury in my hand.
Select...
My hand's blood flow is good, as checked by my doctor.
Select...
My other hand is fully functional and healthy.
Select...
I can keep my injured hand still after surgery.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a condition that affects my peripheral nervous system.
Select...
My wound with the nerve to be studied is severely infected.
Select...
I have an infection near my nerve injury.
Select...
My vital signs are stable.
Select...
I have existing nerve damage or diagnosed nerve compression in my arms.
Select...
I have had an injury or was born with a condition in my hand or arm that could affect nerve healing.
Select...
The nerve needing repair in my body controls both movement and sensation.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
The primary objective of this study is to evaluate return to sensory recovery with the NeuraGen 3D Nerve Guide Matrix in a small group of subjects with primary nerve injury of the hand.(s2PD) at each post-operative timepoint of the study.
Secondary study objectives
Continuous Visual Analog Scale for Pain at each post-operative timepoint of the study
Disabilities of the Arm, Shoulder and Hand (DASH) Score at each post-operative timepoint of the study
Grip Strength Test at each post-operative timepoint of the study
+4 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: NeuraGen 3D Nerve Guide MatrixExperimental Treatment1 Intervention
Integra NeuraGen 3D Nerve Guide Matrix is a resorbable implant for the repair of peripheral nerve gaps.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for digital nerve injury include surgical repair, nerve grafting, and the use of nerve guide conduits like the NeuraGen 3D Nerve Guide Matrix. Surgical repair involves direct suturing of the nerve ends, while nerve grafting uses a segment of another nerve to bridge the gap. Nerve guide conduits provide a scaffold that supports and directs the growth of regenerating nerve fibers across the injury site. These treatments are crucial as they aim to restore nerve continuity, promote axonal growth, and ultimately recover sensory and motor functions, which are vital for the patient's hand functionality and quality of life.

Find a Location

Who is running the clinical trial?

Integra LifeSciences CorporationLead Sponsor
108 Previous Clinical Trials
11,293 Total Patients Enrolled
Maria LeonardStudy DirectorIntegra LifeSciences

Media Library

NeuraGen 3D Nerve Guide Matrix (Nerve Guide Matrix) Clinical Trial Eligibility Overview. Trial Name: NCT05343143 — N/A
Nerve Damage Research Study Groups: NeuraGen 3D Nerve Guide Matrix
Nerve Damage Clinical Trial 2023: NeuraGen 3D Nerve Guide Matrix Highlights & Side Effects. Trial Name: NCT05343143 — N/A
NeuraGen 3D Nerve Guide Matrix (Nerve Guide Matrix) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05343143 — N/A
~0 spots leftby Nov 2025